

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

**CHANGE OF COMPANY SECRETARY,
AUTHORIZED REPRESENTATIVE
AND
PROCESS AGENT**

The board of directors (the “**Board**”) of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”) hereby announces that Ms. Leung Suet Wing (“**Ms. Leung**”) has resigned from her positions as the company secretary, an authorized representative (the “**Authorized Representative**”) of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) due to work re-arrangement, with effect from July 30, 2021. Ms. Leung has confirmed that there is no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to her resignation.

The Board is also pleased to announce that Mr. Lee Kwok Fai Kenneth (“**Mr. Lee**”) has been appointed as the company secretary, the Authorized Representative and the Process Agent in place of Ms. Leung, with effect from July 30, 2021.

Mr. Lee is a director and head of global entity management division of TMF Hong Kong Limited, which is a corporate secretarial services provider. He has over 20 years of experience in providing transaction and consulting service. He is a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants and a Chartered Financial Analyst.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Leung for her contribution to the Company during her tenure of services, and to express its welcome to Mr. Lee on his new appointment.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾(開曼)有限公司*
Yiping James Li
Chairman

Shanghai, PRC, July 30, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Mr. Hans Edgar Bishop, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Yanling Cao, Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* *For identification purpose only*